- Home
- ANIK vs LENZ Comparison
ANIK vs LENZ Comparison
Compare ANIK & LENZ Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | ANIK | LENZ |
|---|---|---|
| Founded | 1983 | 2019 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Medical/Dental Instruments | Medicinal Chemicals and Botanical Products |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 198.9M | 198.8M |
| IPO Year | 1996 | 2021 |
Fundamental Metrics
Financial Performance| Metric | ANIK | LENZ |
|---|---|---|
| Price | $14.42 | $6.15 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 1 | 5 |
| Target Price | $17.00 | ★ $44.00 |
| AVG Volume (30 Days) | 53.8K | ★ 557.7K |
| Earning Date | 04-29-2026 | 05-06-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 80.16 | N/A |
| EPS | ★ N/A | N/A |
| Revenue | ★ $112,819,000.00 | $19,088,000.00 |
| Revenue This Year | $5.98 | $50.42 |
| Revenue Next Year | $7.42 | $197.16 |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $7.90 | $5.84 |
| 52 Week High | $16.24 | $50.19 |
Technical Indicators
Market Signals| Indicator | ANIK | LENZ |
|---|---|---|
| Relative Strength Index (RSI) | 46.27 | 31.55 |
| Support Level | $13.91 | N/A |
| Resistance Level | $15.08 | $10.42 |
| Average True Range (ATR) | 0.48 | 0.43 |
| MACD | -0.04 | -0.00 |
| Stochastic Oscillator | 46.27 | 14.42 |
Price Performance
Historical ComparisonAbout ANIK Anika Therapeutics Inc.
Anika Therapeutics Inc operates in the OA Pain Management and regenerative solutions space, focusing on early intervention orthopedics. The company leverages proprietary hyaluronic acid (HA) technology to develop differentiated products and provides products and services. Its OA Pain Management products include Orthovisc, Monovisc, and Cingal. Monovisc and Orthovisc are single- and multi-injection HA viscosupplement products indicated for pain relief from OA conditions and are generally administered to patients in an office setting. In the United States, Monovisc and Orthovisc are marketed exclusively by Johnson & Johnson MedTech. It generates maximum revenue from the OEM Channel and derives the majority of its revenue from the United States, with a presence in Europe and other countries.
About LENZ LENZ Therapeutics Inc.
LENZ Therapeutics Inc is a late-stage biopharmaceutical company focused on developing and commercializing therapies to improve vision and developing ophthalmic pharmaceutical products. Its products VIZZ (aceclidine ophthalmic solution) 1.44% is a once-daily eye drop developed to restore clear near vision for up to 10 hours. VIZZ is powered by aceclidine, highlighted by its differentiated mechanism of action as a predominantly pupil-selective miotic that interacts with the iris, with minimal ciliary muscle stimulation.